neratinib
E902878
EGFR inhibitor
HER2 inhibitor
antineoplastic agent
orally administered drug
small molecule drug
tyrosine kinase inhibitor
Neratinib is an oral tyrosine kinase inhibitor used primarily in the treatment of HER2-positive breast cancer, often as extended adjuvant therapy after trastuzumab.
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
EGFR inhibitor
ⓘ
HER2 inhibitor ⓘ antineoplastic agent ⓘ orally administered drug ⓘ small molecule drug ⓘ tyrosine kinase inhibitor ⓘ |
| administeredWithFood | yes ⓘ |
| belongsToClass | pan-HER inhibitors ⓘ |
| bindsCovalentlyTo |
EGFR kinase domain
NERFINISHED
ⓘ
HER2 kinase domain ⓘ |
| contraindication | severe hepatic impairment ⓘ |
| developer | Puma Biotechnology NERFINISHED ⓘ |
| drugInteraction |
strong CYP3A4 inducers
ⓘ
strong CYP3A4 inhibitors ⓘ |
| eliminationRoute | fecal ⓘ |
| hasApprovalYear | 2017 ⓘ |
| hasATCCode | L01EB03 ⓘ |
| hasBlackBoxWarning | diarrhea risk ⓘ |
| hasCASNumber | 698387-09-6 ⓘ |
| hasCommonAdverseEffect |
abdominal pain
ⓘ
decreased appetite ⓘ diarrhea ⓘ fatigue ⓘ nausea ⓘ rash ⓘ stomatitis ⓘ vomiting ⓘ |
| hasDosageForm | oral tablet ⓘ |
| hasDosingSchedule | once daily ⓘ |
| hasINN | neratinib NERFINISHED ⓘ |
| hasMolecularFormula | C30H29ClN6O3 ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasSeriousAdverseEffect |
hepatotoxicity
ⓘ
severe diarrhea ⓘ |
| hasUSBrandName | Nerlynx NERFINISHED ⓘ |
| indication |
HER2-positive breast cancer
ⓘ
adjuvant therapy after trastuzumab-based treatment ⓘ extended adjuvant treatment of early-stage HER2-positive breast cancer ⓘ |
| mechanismOfAction | irreversible pan-HER tyrosine kinase inhibition ⓘ |
| metabolism | CYP3A4-mediated ⓘ |
| regulatoryApproval |
EMA-approved
ⓘ
FDA-approved ⓘ |
| requiresMonitoring | liver function tests ⓘ |
| requiresProphylaxis | antidiarrheal medication ⓘ |
| targets |
EGFR
NERFINISHED
ⓘ
ERBB1 NERFINISHED ⓘ ERBB2 NERFINISHED ⓘ HER2 NERFINISHED ⓘ |
| usedAs | extended adjuvant therapy ⓘ |
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.